Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

• Autoři: ANTUNES Liliana; MAZAGATOS Clara; MARTÍNEZ-BAZ Iván; GOMEZ Verónica; MARIA-LOUISE Borg; PETROVIĆ Goranka; DUFFY Róisín; DUFRASNE François E; DÜRRWALD Ralf; LAZAR Mihaela; JANCORIENE Ligita; OROSZI Beatrix; HUSA Petr; HOWARD Jennifer; MELO Aryse; POZO Francisco; PÉREZ-GIMENO Gloria; CASTILLA Jesús; MACHADO Ausenda; DŽIUGYTE Aušra; KARABUVA Svjetlana; FITZGERALD Margaret; FIERENS Sébastien; TOLKSDORF Kristin; SILVIA-ODETTE Popovici; MICKIENE Aukse; TÚRI Gergő; SOUČKOVÁ Lenka; NICOLAY Nathalie; ROSE Angela Mc
• Rok publikování: 2024
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: EUROSURVEILLANCE
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content
• Doi: http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708
• Klíčová slova: bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network
• Popis: We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged???60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated >?6 months before the campaign: from 80% (95%?CI: 50?to?94) for 14–89 days post-vaccination, 15% (95%?CI: -12?to?35) at 90–179 days, and lower to no effect thereafter.